Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
24.08
+0.23 (0.96%)
Mar 18, 2026, 4:00 PM EDT - Market closed
Pelthos Therapeutics Revenue
Pelthos Therapeutics had revenue of $7.41M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $7.41M.
Revenue (ttm)
$7.41M
Revenue Growth
n/a
P/S Ratio
10.52
Revenue / Employee
$673,273
Employees
11
Market Cap
77.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 199.93K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NeurAxis | 3.36M |
| BeyondSpring | 1.88M |
| Seres Therapeutics | 789.00K |
| Spruce Biosciences | 697.00K |
| MediciNova | 409.66K |
| iBio, Inc. | 300.00K |
PTHS News
- 6 days ago - Pelthos Therapeutics to Present at 38th Annual ROTH Conference - GlobeNewsWire
- 2 months ago - Horizon Technology Finance Provides up to $50 Million Venture Loan Facility to Pelthos Therapeutics - Business Wire
- 2 months ago - Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance - GlobeNewsWire
- 2 months ago - Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice - GlobeNewsWire
- 3 months ago - Pelthos Pharmaceuticals: Off To A Strong Start With Zelsuvmi, Continued Sales Growth Is Likely - Seeking Alpha
- 4 months ago - Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results - GlobeNewsWire
- 4 months ago - Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing - GlobeNewsWire